New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free

Friday, November 13, 2026

Back to the front page

From X

Multiples Capital on X

I recently sat down with @StockJabber at @IdeaBrunchEmail to discuss the strategy behind Multiples Capital's outperformance in 2025. The full interview is behind a paywall, but here are 4 core themes we discussed: 1/ The Multi-Asset Edge While many leaned on the "Magnificent 7," we found alpha in global de-dollarization and the massive electricity demands of AI data centers. This approach delivered a 3.15 Sharpe Ratio—with roughly half the turbulence of the S&P 500. 2/ Garrett Motion ($GTX) Update Since my last feature, $GTX has surged ~170%. We discussed the "perfect storm" of index inclusion and aggressive capital allocation that drove this run, and why the "EV-only" fear proved to be premature. 3/ AI Disruption vs. Mispricing The market is correctly identifying "AI Losers" in SaaS, but it’s applying that same anxiety with broad stroke. We broke down why Expedia ($EXPE) is a prime example of this mispricing, trading at a 12%+ FCF yield despite its essential role in the global travel ecosystem and it's growing B2B setment. 4/ My Favorite "Tokenization" Play We closed with a deep dive into the digitalization of finance. I shared my top idea for playing the tokenization trend, a company currently acting as the "digital infrastructure provider" for institutions and growing it's subscription and service revenues. Read the full deep dive here: Note: As this is premium content, I cannot share the PDF on a open platform. However, if you’d like to join my quarterly investor letter distribution list to see how we are positioning for the "Broadening Trade" in 2026, please send a DM.

QXO Inc Earnings Update: Q3 2026

QXO's Q3 sales rose 79% to $4.9 billion after TopBuild and Kodiak acquisitions, while acquisition debt lifted interest expense to $163…

Cerrado Gold: Research Note

Cerrado Gold will acquire Argentina’s Manantial Espejo mine from Pan American Silver for $20 million and targets a 2027 restart funded by…

Qure Anniversary Update

UniQure’s Huntington’s disease BLA has a May 1, 2027 priority-review date, with an FDA advisory committee expected in late first quarter.

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.